Immupharma Share Discussion Threads

[ny boy] 26/2/2019 07:41

Ureka ..we have an rns 😄

[master rsi] 25/2/2019 22:53

The full article
IMM - mmuPharma continues to build data package for flagship lupus treatment-
Pro active Investors 15:30, 25 Feb 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year

Flagship drug is Lupuzor – a treatment for lupus
Results from follow-up study due within next few months
Nucant cancer treatment also going through the clinic
Ureka subsidiary being divested

What it does
ImmuPharma PLC (LON:IMM) specialises in developing drugs for serious medical conditions for which there is a distinct lack of existing treatments.

Its flagship drug is called Lupuzor – a treatment for the autoimmune disease lupus.

The drug missed its primary endpoint in a phase II study last year, but the outcome was more nuanced than the top line results suggested and actually showed that Lupuzor worked well in certain patients, chiefly those who were antibody-positive.

The results certainly haven’t held back ImmuPharma or its top drug. In fact, boss Tim McCarthy has said that Lupuzor still possesses “blockbuster potential”, meaning it could rack more than US$1bn in annual sales.

After the end of the phase III trial, 62 patients took part in a ‘follow-up’ study – called an open-label extension study. Results from this are expected between April and June.

On top of that, another 500 lupus sufferers are being given access to Lupuzor for the next two years as part of a managed access programme.

In addition to helping patients, the AIM-quoted drug developer expects to collect more valuable data on Lupuzor, which will be useful if and when it decides to press ahead with regulatory filings.

Blue sky
In the immediate future, results from the Lupuzor follow-up study are due by the end of June, while the managed access programme is set to complete towards the end of 2020.

Should Lupuzor prove itself in those two tests, ImmuPharma will use the data to try to get full regulatory approval the drug, something bosses hope to achieve “in the medium term”.

Lupuzor isn’t ImmuPharma’s only drug going through the clinic. Its Nucant cancer treatment has yielded “promising results” in two phase I safety and dose-finding studies.

The company has signed heads of terms on a clinical development collaboration with oncology specialist Incanthera, in which ImmuPharma has taken a £2mln stake.

A licence agreement between the two is expected to be signed by the end of March, a deal which is likely to see Incanthera pay an upfront licence fee of £1mln in shares and cover all the development costs for the Nucant programme.

All future commercialisation revenues will be shared equally, ImmuPharma has said.

[nobbygnome] 25/2/2019 21:02

Miserably. P value 0.2631.....not even vaguely close to significance!

[ken chung] 25/2/2019 20:58

Lupuzor failed Phase 3.

[kirk 6] 25/2/2019 18:02

Summary ......Flagship drug is Lupuzor – a treatment for lupusResults from follow-up study due within next few monthsNucant cancer treatment also going through the clinicUreka subsidiary being divested

[kirk 6] 25/2/2019 18:01

Excellent article out late this afternoon https://www.proactiveinvestors.co.uk/companies/news/215247/immupharma-continues-to-build-data-package-for-flagship-lupus-treatment-215247.html#The share price should move much higher tomorrow

[ny boy] 25/2/2019 16:26

Buying boots on , action!

[a_2_b] 25/2/2019 16:17

Mr 25k doesn't seem too put off

[ny boy] 25/2/2019 14:35

Everyone waiting for another bottom for another pump to 17p + lol

[ny boy] 25/2/2019 11:48

As I suspected no buyers and no posts, looks like everyone has moved onto the next target.

Unless they pull in millions in a licensing deal soon, I reckon they will be short of funds before end of H1, Difficult to raise monies after the last one, unless there is substance.

[ny boy] 25/2/2019 09:18

Maximum investment excitement here today 🙄

[buywell3] 24/2/2019 19:00

what is a placebo ? read this


buywell3 - 27 Apr 2018 - 10:19:34 - 29505 of 33977 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM
Phase 3 trials are very pricey

To sign up a meaningful number of human guinea pigs to be injected with a trial drug compound ... with unknown toxicology outcomes ... you could be looking at several millions of pounds.

Where is the money coming from after the recent Phase 3 results came out poor at best ie no proven efficay ie the compound didn't do anything measurable that was different to a placebo ie a fake drug/pill that some human guinea pigs have to take at phase 3 in order to see if those taking the real deal drug being tested derive any benefit from taking it ie it has efficacy.

efficacy is the whole reason for a phase 3 clinical trial to see if the drug being tested works

Put me down for one of those please nurse

[nobbygnome] 24/2/2019 14:34

Not on IMM I should stress as I have no position here. Wouldn't touch it with a barge pole but also not short.

[nobbygnome] 24/2/2019 14:33

LOL! It is where I am making lots of money....

[kirk 6] 24/2/2019 14:09

Now your retired is this were you find happiness and companionship?

[nobbygnome] 24/2/2019 14:03

LOL! Less than a year since I left the profession; I don't think the pharmaceutical industry changes that quickly!

Very unlikely in Lupus because it is well known to be a waxing waning disease with a very high placebo rate.

[a_2_b] 24/2/2019 13:51

I'd say anything is possible personally, unfortunately Nobby is apparently a retired professional in a constantly evolving field so I would not take anything he says seriously at all. I'd take a look at this link personally before making any judgement:

www.wepclinical.com/managed-access-programs/

'There are examples of investigational drug being approved on the back of real world data collected during Managed Access Programs.'

[asat91] 23/2/2019 23:13

I hate to agree with nobby but he's right it's very unlikely that open label data will be able to be used in an application for FDA/EU approval because there is no placebo group.

It's well documented how much the placebo effect can change the outcome of treatments especially when measures include self report aspects.

[nobbygnome] 23/2/2019 16:07

Don't expect too much from the open label results. They will not be submissable to the regulators because there is no placebo group. Plus of course SLE is a waxing waning disease so open label results really can't be trusted. The management here continue to waste the shareholders' money....

[brad44] 23/2/2019 14:35

wish tim mcartney would put you into administration..on another note, stick some noodles and cashew with that lemming and mushroom, a bit of sauce and call it no63

[ken chung] 22/2/2019 22:12

Lemmings and mushrooms only.

Just a lifestyle company now for the managers until the cash runs out.

See how Tim McCartney led Alizyme into administration - all four drugs failed or were worthless.

No difference here.

[spawny100] 22/2/2019 18:07

30p soon kirk

[kirk 6] 22/2/2019 16:09

Heavy buying now into close

[ny boy] 22/2/2019 14:40

What are the guys saying on lse, one of them heard rumours of aplacing just before the January £10M one, sounds like a few of them know more than most PI’s

Tim, if you watch his proactive interviews is always very up beat about everything, he’s a good sales guy. Trouble is the interviewers rarely ask them anything searching questions, it’s all very nice questions! It’s really time this Company delivers before the cash runs out, I doubt they have much cash left to go beyond Q2 imo

[kop202] 22/2/2019 13:19

Oh dear yet another bull trap.....was this Tim's idea